Yes - the first people adopting most of the new longevity therapies are going to be people like us, people with higher risk/reward tolerances, signing up to participate in the clinical trials.
Keep in mind, that the vast majority of new therapies fail for some reason (bad side effects, efficacy, etc.) during early clinical trials. And even if a drug is approved by the FDA, this only means it worked for a few months for a few thousand people - you have no idea of the long term costs/benefits - so there is still risk. So it would be stupid to start taking things too early, especially if you’re a billionaire. You’d be wrong most of the time, and likely suffer the consequences of early testing of many drugs and therapies. Of course if you’re getting really old and desperate and you’re a dictator, you may take some greater risks (but are unlikely to be successful).
See:
The grim baseline is well known. In 2015, it was estimated that only one in every 5,000 compounds (0.02%) discovered and tested preclinically would get approved; of the drugs started in clinical trials in human participants, only 10% would secure FDA approval. In a later analysis of the period between 2014 and 2023, Citeline estimated the average likelihood of approval (LOA) for a new Phase I drug to be 6.7%, an all-time low. According to Citeline, the leading cause of failure remains the “Phase II hurdle,” with a 28% completion rate compared to Phase I (47%) and Phase III (55%).
Source: Star Scientist’s Claim of ‘Reverse Aging’ Draws Hail of Criticism (WSJ) - #38 by RapAdmin